Yuan Yang

Dr. Yuan Yang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
YDYushan Duan
Yushan Duan
YYYue Yin
Yue Yin
JYJinxi Yue
Jinxi Yue
WZWeihua Zhu
Weihua Zhu
XYXiumei Yang
Xiumei Yang
YYYuan Yang
Yuan Yang
In this study, we performed a meta-analysis to systematically evaluate how restrictive fluid resuscitation strategies, compared to conventional approaches, affect key clinical outcomes in adult patients with septic shock in the intensive care unit (ICU). The primary outcomes of our analysis included acute kidney injury incidence and ICU mortality, while the secondary outcomes encompassed mechanical ventilation requirement and ischemic event incidence. By comparing the efficacy and safety of the two strategies, this study provides evidence-based support for optimizing fluid management in patients with septic shock. A systematic search of the PubMed, Cochrane Library, Web of Science, Embase, and CNKI databases was performed from inception to March 2024. Randomized controlled trials on restrictive fluid resuscitation for septic shock were included. Primary outcomes included acute kidney injury incidence and ICU mortality; secondary outcomes covered mechanical ventilation requirement and ischemic events. The meta-analysis was performed using Review Manager software (version 5.3). Five randomized controlled trials were included in this study, comprising 1972 patients. Compared to the conventional fluid resuscitation group, the restrictive fluid resuscitation group displayed no difference in acute kidney injury incidence (risk ratio (RR), 0.92; 95% confidence interval (CI), 0.79–1.07; P = 0.29; I2 = 0%), ICU mortality (RR, 1.00; 95%CI 0.9–1.12; P = 0.96; I2 = 0%), mechanical ventilation (RR, 0.96; 95%CI, 0.74–1.23; P = 0.74; I2 = 0%), and ischemic event rate (RR, 0.92; 95%CI, 0.31–2.68; P = 0.87; I2 = 58%). Limitations included the small number of included studies and moderate heterogeneity in ischemic event outcomes. Although restrictive fluid resuscitation did not show superiority over conventional protocols in terms of clinical outcomes, it may represent a safe alternative for ICU patients with septic shock. The study was registered on PROSPERO (CRD42024515869).

21 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YDYushan Duan
Yushan Duan
XWXiaohong Wan
Xiaohong Wan
YMYiming Ma
Yiming Ma
WZWeihua Zhu
Weihua Zhu
YYYue Yin
Yue Yin
YYYuan Yang
Yuan Yang
Objective: To investigate the efficacy and safety of high-dose tranexamic acid in different types of surgeries and provide a reference for clinical practice.Methods: We systematically searched PubMed, Cochrane Library, Science, Embase, and CNKI databases, from their inception to January 2025, to include representative literature related to high-dose tranexamic acid in the perioperative period for a thematic synthesis. The analysis focused on clinical evidence related to obstetric, cardiac, urologic, orthopedic, and spinal surgeries.Results: High-dose tranexamic acid markedly reduces blood loss and transfusion requirements in most types of surgery; however, the optimal dose varies by surgery type. Available studies have shown a favorable safety profile; however, some areas (e.g., cardiac surgery) still require careful monitoring for seizures and risk of thrombotic events.Conclusion: The clinical benefit of high-dose tranexamic acid should be assessed based on surgical characteristics and patient individualization. More multicenter studies are needed to clarify the dose-effect relationship and long-term safety.